Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against TransEnterix Inc. and Encourages Investors With Losses to Contact the Firm

SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against TransEnterix Inc. and Encourages Investors With Losses to Contact the Firm

Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against TransEnterix Inc. ("TransEnterix" or the "Company") (NYSE: TRXC). Investors who purchased or otherwise acquired shares between February 10, 2016 and May 20, 2016 (the “Class Period”), are encouraged to contact the firm in advance of the August 1, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, the Company made false and/or misleading statements and/or failed to disclose that: there were deficiencies within the Company's 510(k) submission regarding the SurgiBot that undermined the likelihood that the SurgiBot would receive clearance from the Food and Drug Administration, which would leave TransEnterix unable to commercialize the SurgiBot in 2016, and would impair the Company's ability to obtain approval for and commercialize its other robotic surgery platform in the United States.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401
info@goldberglawpc.com